The values and corporate philosophy of Talkmed Group Ltd encompass a strong commitment to excellence in healthcare services. With a focus on patient-centric care, Talkmed Group Ltd strives to provide high-quality, comprehensive medical solutions. The company emphasizes professionalism, integrity, and innovation in its operations, aiming to deliver the best possible outcomes for patients. With a dedicated team of medical professionals and cutting-edge technology, Talkmed Group Ltd continuously seeks to enhance its services and expand its expertise, all while maintaining a patient-centered approach.

Talkmed Group Ltd is primarily present in Singapore.

Talkmed Group Ltd has achieved several significant milestones in its history. The company has successfully established itself as a leading provider of integrated oncology services in Singapore and the region. Talkmed Group Ltd has received numerous accolades and recognition for its dedication to delivering high-quality and comprehensive cancer care. The company has also built strong partnerships with key medical institutions and renowned oncologists, cementing its position as a trusted and reliable player in the field. With its commitment to innovation and patient-centric care, Talkmed Group Ltd continues to make strides in the oncology industry, driving positive outcomes for patients and their families.

Talkmed Group Ltd, a leading healthcare provider in Singapore, has an intriguing history and background. Established in 2005, the company was founded by Dr. Ang Peng Tiam, a renowned medical oncologist. Talkmed Group Ltd primarily focuses on the provision of specialized medical services, particularly in the field of oncology. Building upon their commitment to quality care, Talkmed Group Ltd has partnered with numerous local and international hospitals, enabling them to expand their reach and offer exceptional healthcare services to a broader patient base. With their team of highly qualified healthcare professionals and state-of-the-art facilities, Talkmed Group Ltd continues to make significant contributions to the medical industry, solidifying their position as a trusted name in healthcare.

The main competitors of Talkmed Group Ltd in the market include Raffles Medical Group, Singapore Medical Group, and Q&M Dental Group.

Talkmed Group Ltd is primarily active in the healthcare industry.

The business model of Talkmed Group Ltd involves providing integrated healthcare services, specializing in cancer treatment and medical oncology. As a leading medical group in Singapore, Talkmed focuses on delivering personalized and comprehensive care to patients, employing a multidisciplinary approach. The company collaborates with other healthcare providers and maintains close relationships with top hospitals and medical professionals. Talkmed offers a range of services such as clinical research, telemedicine, oncology training, and consultancy services. By combining advanced medical technology, research, and expertise, Talkmed Group Ltd aims to improve patient outcomes and enhance the quality of cancer care.

Talkmed Group KGV ir 0.

Talkmed Group KUV ir 8,05.

AlleAktien kvalitātes vērtējums Talkmed Group ir 7/10.

gaidāmā Talkmed Group apgrozījums ir 67,03 milj. SGD.

Pašlaik peļņa Talkmed Group nevar tikt aprēķināta.

The Talkmed Group Ltd is a publicly traded company based in Singapore. It operates in various areas of medicine, providing both clinical and diagnostic services. In addition, it specializes in the development of medical devices and technologies. Clinical services Talkmed is one of the leading cancer specialists in Asia, offering a wide range of clinical services including oncology, hematology, surgery, radiation therapy, cardiology, and neurology. These services are provided by experienced doctors and specialists who work closely with patients to achieve the best treatment outcomes. Diagnostic services Talkmed Group Ltd offers specialized diagnostic services such as pathology, radiology, and nuclear medicine. These services are crucial for detecting diseases and are therefore an important preventative measure. Development of medical devices and technology The company also specializes in developing medical devices and technologies to improve clinical and diagnostic services. One of its key products is the OncoSweep technology, which enables doctors to quickly and effectively detect cancer cells and tissues. Other products Talkmed also offers pharmaceutical products, either developed by third parties or produced by themselves. These products are used in combination with clinical and diagnostic services to provide better treatment outcomes for patients. Business model Talkmed Group Ltd's business model is based on providing high-quality clinical and diagnostic services. They strive to offer the best medical care by utilizing the latest technologies and procedures and employing experienced and qualified professionals. Talkmed Group earns its revenue by billing patients and insurance companies for the services provided. However, the company also aims to expand its presence in the market by participating in or acquiring other companies. It also has a strong presence in Southeast Asia, where there is great potential in the healthcare industry. In summary, Talkmed Group Ltd's business model is focused on providing high-quality clinical and diagnostic services to improve patients' lives. The company also has a strong commitment to developing new medical devices and technologies to enhance diagnostic accuracy and the effectiveness of clinical services. Talkmed Group Ltd will continue to grow in the future as there is a high demand in the healthcare industry.

Talkmed Group izmaksā dividendes 0,02 SGD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Talkmed Group vai uzņēmums nedod dividendes.

Talkmed Group ISIN ir SG2G61000003.

Talkmed Group simbols ir 5G3.SI.

Pēdējo 12 mēnešu laikā Talkmed Group maksāja dividendes 0,02 SGD apmērā. Tas atbilst aptuveni 5,93 % dividendes ražībai. Nākamajos 12 mēnešos Talkmed Group plāno maksāt dividendes 0,02 SGD apmērā.

Talkmed Group pašreizējā dividendu rentabilitāte ir 5,93 %.

Talkmed Group maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos maijs, septembris, maijs, septembris.

Talkmed Group pēdējo 11 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0,02 SGD. Tas atbilst dividendes ražībai 5,93 %.

Talkmed Group tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Talkmed Group apmērā 0,009 SGD, kas tika izmaksāta 22.08.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 14.08.2024..

Pēdējās dividendes izmaksa notika 22.08.2024..

Gadā 2023, Talkmed Group izmaksāja 0,024 SGD dividendes.

Talkmed Group dividendes tiek izmaksātas SGD.